Short Interest in Bionomics Limited (NASDAQ:BNOX) Grows By 1,279.0%

Bionomics Limited (NASDAQ:BNOX) was the target of a significant increase in short interest in October. As of October 31st, there was short interest totalling 190,300 shares, an increase of 1,279.0% from the October 15th total of 13,800 shares. Based on an average trading volume of 9,160,000 shares, the short-interest ratio is presently 0.0 days.

Bionomics Stock Down 8.9 %

Shares of Bionomics stock traded down $0.03 during trading on Tuesday, hitting $0.34. 1,414,897 shares of the stock traded hands, compared to its average volume of 3,089,015. The company has a fifty day moving average price of $0.42 and a two-hundred day moving average price of $0.65. Bionomics has a twelve month low of $0.18 and a twelve month high of $2.19.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Bionomics in a research note on Thursday, August 1st.

Institutional Investors Weigh In On Bionomics

An institutional investor recently bought a new position in Bionomics stock. Armistice Capital LLC acquired a new stake in Bionomics Limited (NASDAQ:BNOX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned 15.03% of Bionomics at the end of the most recent quarter. 15.90% of the stock is owned by institutional investors and hedge funds.

About Bionomics

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.